Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer.
Alhuseinalkhudhur A, Lindman H, Liss P, Sundin T, Frejd FY, Hartman J, Iyer V, Feldwisch J, Lubberink M, Rönnlund C, Tolmachev V, Velikyan I, Sörensen J. Alhuseinalkhudhur A, et al. Among authors: hartman j. J Nucl Med. 2023 Sep;64(9):1364-1370. doi: 10.2967/jnumed.122.265364. Epub 2023 Jul 13. J Nucl Med. 2023. PMID: 37442602 Free PMC article. Clinical Trial.
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
Hatschek T, Foukakis T, Bjöhle J, Lekberg T, Fredholm H, Elinder E, Bosch A, Pekar G, Lindman H, Schiza A, Einbeigi Z, Adra J, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Agartz S, Azavedo E, Grybäck P, Hellström M, Johansson H, Maes C, Zerdes I, Hartman J, Brandberg Y, Bergh J. Hatschek T, et al. Among authors: hartman j. JAMA Oncol. 2021 Sep 1;7(9):1360-1367. doi: 10.1001/jamaoncol.2021.1932. JAMA Oncol. 2021. PMID: 34165503 Free PMC article. Clinical Trial.
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.
Matikas A, Johansson H, Grybäck P, Bjöhle J, Acs B, Boyaci C, Lekberg T, Fredholm H, Elinder E, Margolin S, Isaksson-Friman E, Bosch A, Lindman H, Adra J, Andersson A, Agartz S, Hellström M, Zerdes I, Hartman J, Bergh J, Hatschek T, Foukakis T. Matikas A, et al. Among authors: hartman j. Clin Cancer Res. 2023 Feb 1;29(3):532-540. doi: 10.1158/1078-0432.CCR-22-2829. Clin Cancer Res. 2023. PMID: 36449695 Clinical Trial.
Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study.
Acs B, Hartman J, Sönmez D, Lindman H, Johansson ALV, Fredriksson I. Acs B, et al. Among authors: hartman j. Lancet Reg Health Eur. 2024 Mar 19;40:100886. doi: 10.1016/j.lanepe.2024.100886. eCollection 2024 May. Lancet Reg Health Eur. 2024. PMID: 38745990 Free PMC article.
PIK3CA mutations in endocrine-resistant breast cancer.
Schagerholm C, Robertson S, Toosi H, Sifakis EG, Hartman J. Schagerholm C, et al. Among authors: hartman j. Sci Rep. 2024 May 31;14(1):12542. doi: 10.1038/s41598-024-62664-1. Sci Rep. 2024. PMID: 38822093 Free PMC article.
1,107 results